203 related articles for article (PubMed ID: 2438894)
41. [A retrospective analysis of the treatment results in Hodgkin's disease in a radiotherapy clinic].
Mjaaland I; Ganser D; Freitag EM; Bohndorf W
Strahlenther Onkol; 1994 Sep; 170(9):516-23. PubMed ID: 7524173
[TBL] [Abstract][Full Text] [Related]
42. MOPP, ABVD, or both to treat Hodgkin's disease.
Martino R; Nomdedeu J; Brunet S
N Engl J Med; 1993 Apr; 328(14):1045; author reply 1045-6. PubMed ID: 7680766
[No Abstract] [Full Text] [Related]
43. Hodgkin's disease and the risk of acute leukemia in successfully treated patients.
Valagussa P; Bonadonna G
Haematologica; 1998 Sep; 83(9):769-70. PubMed ID: 9825571
[No Abstract] [Full Text] [Related]
44. Chemotherapy in the treatment of Hodgkin's disease.
Canellos GP; Come SE; Skarin AT
Semin Hematol; 1983 Jan; 20(1):1-24. PubMed ID: 6189191
[No Abstract] [Full Text] [Related]
45. ABVD in the treatment of Hodgkin's disease.
Bonfante V; Santoro A; Viviani S; Valagussa P; Bonadonna G
Semin Oncol; 1992 Apr; 19(2 Suppl 5):38-44; discussion 44-5. PubMed ID: 1384143
[TBL] [Abstract][Full Text] [Related]
46. Doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) salvage of mechlorethamine, vincristine, prednisone, and procarbazine (MOPP)-resistant advanced Hodgkin's disease.
Piga A; Ambrosetti A; Todeschini G; Cetto G; Perona G; Cellerino R
Cancer Treat Rep; 1984; 68(7-8):947-51. PubMed ID: 6204754
[TBL] [Abstract][Full Text] [Related]
47. Comparison of MOPP/MOPP +/- RT vs. MOPp/ABVD +/- RT in poor prognosis Hodgkin's disease. Long-term results.
Comella P; Abate G; Fiore M; Di Finizio G; Frezza P; Scoppa G; Anania C; Coucourde F; Zarrilli D
J Chemother; 1989 Jul; 1(4 Suppl):1254-6. PubMed ID: 16312855
[No Abstract] [Full Text] [Related]
48. Analysis of the risk of solid tumor following Hodgkin's disease.
Maurizi Enrici R; Anselmo AP; Osti MF; Santoro M; Tombolini V; Mandelli F; Biagini C
Haematologica; 1997; 82(1):57-63. PubMed ID: 9107084
[TBL] [Abstract][Full Text] [Related]
49. Clinical dose-volume histogram analysis in predicting radiation pneumonitis in Hodgkin's lymphoma.
Koh ES; Sun A; Tran TH; Tsang R; Pintilie M; Hodgson DC; Wells W; Heaton R; Gospodarowicz MK
Int J Radiat Oncol Biol Phys; 2006 Sep; 66(1):223-8. PubMed ID: 16904523
[TBL] [Abstract][Full Text] [Related]
50. [Improved survival rates in Hodgkin's disease].
Hayabuchi N; Jingu K; Miyoshi M; Hirata H; Masuda K; Shibuya T; Nishimura J; Komiyama S; Ishii E; Kikuchi M
Gan No Rinsho; 1988 Apr; 34(5):698-704. PubMed ID: 2455073
[TBL] [Abstract][Full Text] [Related]
51. ChlVPP/ABVVP, a first line 'hybrid' combination chemotherapy for advanced Hodgkin's lymphoma: a retrospective analysis.
Martinelli G; Cocorocchio E; Peccatori F; Zucca E; Saletti PC; Calabrese L; Pastano R; Pruneri G; Mazzetta C; Ghielmini M; Cavalli F
Br J Haematol; 2004 Jun; 125(5):584-9. PubMed ID: 15147373
[TBL] [Abstract][Full Text] [Related]
52. [The chemotherapeutic treatment of advanced Hodgkin's disease].
Epelbaum R; Haim N; Ben-Shahar M; Valtuch I; Faraggi D; Sharabi-Nov A; Ben-Arie Y; Cohen Y
Harefuah; 2001 Apr; 140(4):311-5, 367. PubMed ID: 11303395
[TBL] [Abstract][Full Text] [Related]
53. Avascular necrosis of the femoral head after treatment of Hodgkin's disease.
Tombolini V; Capua A; Pompili E
Acta Oncol; 1992; 31(1):64-5. PubMed ID: 1375043
[No Abstract] [Full Text] [Related]
54. Super-acute onset of tumor lysis syndrome accompanied by hypercytokinemia during treatment of Hodgkin's lymphoma with ABVD chemotherapy.
Suzuki T; Takeuchi M; Saeki H; Yamazaki S; Koga H; Abe D; Nishimura M; Nakaseko C; Nakasa H; Nakamura H; Ariyoshi N; Kitada M
Clin Ther; 2010 Mar; 32(3):527-31. PubMed ID: 20399989
[TBL] [Abstract][Full Text] [Related]
55. Assessment of male fertility in patients with Hodgkin's lymphoma treated in the German Hodgkin Study Group (GHSG) clinical trials.
Sieniawski M; Reineke T; Josting A; Nogova L; Behringer K; Halbsguth T; Fuchs M; Diehl V; Engert A
Ann Oncol; 2008 Oct; 19(10):1795-801. PubMed ID: 18544558
[TBL] [Abstract][Full Text] [Related]
56. Is escalated BEACOPP a standard therapy for advanced Hodgkin's disease?
Carde P; Cavalli F; Diehl V; Franklin J
Hematol J; 2000; 1(4):282-90. PubMed ID: 11920203
[No Abstract] [Full Text] [Related]
57. Fatal necrosis of the liver during ABVD chemotherapy for Hodgkin's disease. A case report.
Joensuu H; Söderström KO; Nikkanen V
Cancer; 1986 Oct; 58(7):1437-40. PubMed ID: 2427187
[TBL] [Abstract][Full Text] [Related]
58. Gonadal damage in Hodgkin's disease from cancer chemotherapeutic regimens.
Bonadonna G; Santoro A; Viviani S; Lombardi C; Ragni G
Arch Toxicol Suppl; 1984; 7():140-5. PubMed ID: 6083763
[TBL] [Abstract][Full Text] [Related]
59. Intermittent G-CSF to maintain dose intensity of chemotherapy for Hodgkin's disease.
Clarke K; Grigg A
Leuk Lymphoma; 1995 Nov; 19(5-6):521-2. PubMed ID: 8590858
[No Abstract] [Full Text] [Related]
60. Doxorubicin, bleomycin, vinblastine, and dacarbazine alone in treatment of favorable, limited-stage Hodgkin's lymphoma: do we really have robust data?
Basaran G; Agaoglu F; Basaran M
J Clin Oncol; 2010 Sep; 28(27):e485-6; author reply e487. PubMed ID: 20606082
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
